SLC5A2 and diabetes mellitus: The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes trial (EMPA-REG trial) was the first diabetes drug trial showing that a member of the SGLT2 inhibitor class, empagliflozin, not only reduced glucose levels but also improved cardiovascular outcomes in patients with type 2 diabetes, and decreased mortality from all causes (Zinman et al., 2016).